CRISPR Therapeutics AG
NASDAQ:CRSPBiotechnology
+$1.43 today
- Market cap
- $3.90B
- Beta
- 1.70
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$5.92
Volume 3.97M
Average 1.70M
CRSP Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
CRISPR Therapeutics AGNASDAQ: CRSP
Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Financing cash flow dips below year-ago levels
Q3 FY2026 financing cash flow of $4.45M fell 98.5% year over year, behind the +120.5% change in trailing-twelve-month financing cash flow. Sequentially, it fell 38.0% from the prior quarter. Over 3 fiscal years it compounded at +122.7% a year.
Context
- Financing cash flow amounted to 12137.5% of revenue in FY2025, up 11189.0 pp from a year earlier.
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -98.5% toward the trailing-twelve-month pace of +120.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 426.03M USD
- Year-over-year change
- +28.3%
- 4-year CAGR
- +14.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 426.03M | +28.3% |
| FY2024 | 2024-12-31 | 331.98M | +429.8% |
| FY2023 | 2023-12-31 | 62.66M | +62.4% |
| FY2022 | 2022-12-31 | 38.59M | -84.6% |
| FY2021 | 2021-12-31 | 250.95M | — |
Financing Cash Flow vs competitors
How CRSP compares with its peers on the latest reported figures
- CRSP's LTM Sep 2026 financing cash flow of $719.96M is the largest of the 7 companies compared; the peer median is $96.46M.
- Its year-over-year change of +120.5% is the 4th highest of 7, against a peer median of +168.1%.
- Financing cash flow amounts to 2860.1% of revenue for CRSP, versus a peer median of 116.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $719.96M | +120.5% | +122.7% | 2860.1% | |
| LTM Mar 2026 | $165.06M | +31.3% | -31.7% | 249.7% | |
| LTM Mar 2026 | $108.93M | +421.9% | — | 124.0% | |
| LTM Jun 2026 | $107.69M | -77.5% | +62.4% | 69.0% | |
| LTM Mar 2026 | $85.22M | +305.0% | +0.1% | 189.1% | |
| LTM Mar 2026 | $41.91M | -23.0% | +215.9% | 108.3% | |
| LTM Mar 2026 | $17.96M | +1731.5% | -42.9% | 12.7% | |
| Peer median (excluding CRSP) | $96.46M | +168.1% | +0.1% | 116.2% | |
Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 377.66M | (650.18M) | (153.61M) | (366.25M) | (581.6M) |
| Depreciation & Amortization | 17.95M | 24.17M | 19.84M | 19.26M | 19.48M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 102.39M | 97.95M | 81.03M | 86.57M | 72.5M |
| Change in Working Capital | 26.86M | 19.85M | (193.59M) | 156.27M | 71.88M |
| Accounts Receivables | (161K) | 305K | (200M) | 175M | 25M |
| Inventory | (37.51M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 37.51M | 5.16M | (20.25M) | 0 | 44.89M |
| Other Working Capital | 27.02M | 14.38M | 26.66M | (18.73M) | 1.99M |
| Other Non-Cash Items | 14.11M | 12.47M | (14.05M) | (38.62M) | 72.73M |
| Operating Cash Flow | 538.97M | (495.74M) | (260.38M) | (142.77M) | (345.01M) |
| Capital Expenditures | (81.71M) | (37.19M) | (9.47M) | (1.9M) | (914K) |
| Acquisitions (Net) | 953.73M | 221.47M | 0 | 0 | 0 |
| Purchases of Investments | (1.51B) | (1.42B) | (1.07B) | (1.49B) | (1.01B) |
| Sales of Investments | 555.6M | 1.2B | 1.45B | 1.21B | 1.01B |
| Other Investing Activities | (953.73M) | (221.47M) | (2.5M) | 0 | (34M) |
| Investing Cash Flow | (1.04B) | (258.66M) | 374.65M | (280.48M) | (31.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 213.27M | 970K | 62.66M | 300.7M | 426.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 37.68M | 37.62M | 0 | 31.29M | 0 |
| Financing Cash Flow | 250.95M | 38.59M | 62.66M | 331.98M | 426.03M |
| Effect of Forex Changes | (11K) | (80K) | 656K | (21K) | 95K |
| Net Change in Cash | (245.52M) | (715.88M) | 177.59M | (91.29M) | 49.3M |
| Free Cash Flow | 457.27M | (532.93M) | (269.85M) | (144.68M) | (345.93M) |
CRISPR Therapeutics AG
NASDAQ:CRSP
Intrinsic Alpha fair value
Locked
Current Price
$40.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.